Acute Agitation and Aggression Market

Market Overview:

The 7 major acute agitation and aggression markets reached a value of US$ 2.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.9 Billion by 2034, exhibiting a growth rate (CAGR) of 3.92% during 2024-2034.

The acute agitation and aggression market has been comprehensively analyzed in IMARC's new report titled "Acute Agitation and Aggression Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Acute agitation and aggression refer to a heightened state of restlessness and hostility, often characterized by intense emotional arousal and a propensity for violent or disruptive behaviors. Individuals experiencing this condition may display an inability to remain calm, restlessness, verbal outbursts, physical aggression, and a diminished capacity to cope with stressors. The symptoms of the illness can manifest as pacing, shouting, threatening gestures, or even physical violence towards others or objects. This state of emotional distress can arise from various factors, such as medical conditions, substance use, psychiatric disorders, or external stimuli. It is essential to recognize that, while these symptoms can be alarming, they are typically indicative of an underlying issue rather than a standalone disorder. Diagnosing the root cause of acute agitation and aggression involves a comprehensive assessment by medical professionals. This investigation might include a thorough medical history, a physical examination, and potentially laboratory tests to rule out any other health conditions that could be contributing to the symptoms.

The increasing prevalence of various neurobiological factors, like environmental stressors and genetic predisposition, resulting in heightened emotional reactivity and impulsive behavior, is primarily driving the acute agitation and aggression market. In addition to this, the rising incidences of dysregulation in neurotransmitter systems, particularly involving serotonin and dopamine pathways, that can impair responses to external stimuli are also creating a positive outlook for the market. Moreover, the widespread adoption of pharmacological medications, such as antipsychotics, anxiolytics, mood stabilizers, etc., for managing and mitigating acute agitation and aggression is further bolstering the market growth. These drugs act on neural circuits to modulate neurotransmitter imbalances and restore emotional equilibrium in individuals suffering from the disorder. Apart from this, the rising usage of non-pharmacological interventions, including cognitive-behavioral therapies, mindfulness practices, and sensory modulation techniques, to boost emotional self-regulation and conflict resolution skills is acting as another significant growth-inducing factor. Additionally, the emerging popularity of neurostimulation procedures like transcranial magnetic stimulation and deep brain stimulation, since they work by directly modulating neural activity in specific brain regions, thereby influencing neuroplasticity in patients, is expected to drive the acute agitation and aggression market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the acute agitation and aggression market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for acute agitation and aggression and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the acute agitation and aggression market in any manner.

Recent Developments:

• In May 2023, BioXcel Therapeutics, Inc. reported encouraging results for BXCL501, the Company's proprietary, orally dissolving film of dexmedetomidine being studied for the treatment of agitation, in Part 1 of its Phase 3 SERENITY III trial, which was conducted in institutional settings for the acute treatment of bipolar disorder- or schizophrenia-related agitation. These results are expected to allow the beginning of Part 2 for at-home use.
• In May 2023, The United States Food and Drug Administration granted supplementary approval to Rexulti (brexpiprazole) oral tablets for the management of agitation associated with Alzheimer's dementia. It is the first FDA-approved therapy for this condition.

Key Highlights:

• In a meta-analysis, the proportion of patients identified as aggressive throughout their acute psychological treatment ranged between 8% and 44%.
• Alzheimer's disease (AD) and mild cognitive impairment (MCI) raise the likelihood of agitation and aggression. According to a meta-analysis, the prevalence of aggression in patients with AD and MCI was 27.8% and 7.4%, respectively.
• Agitation and aggressive behavior were noticed in 20% of outpatients in the community but in 40%-60% of nursing home residents.
• Multiple studies reveal that agitation affects 50% or more of the 6.7 million adults 65 and older in the United States who have Alzheimer's dementia.
• Although multiple types of aggression occur frequently, verbal aggression accounts for up to 75% of incidents.
• As many as 1.7 million instances of acute agitation are probably treated yearly in the United States emergency departments, with countless more in the prehospital setting.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the acute agitation and aggression market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the acute agitation and aggression market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current acute agitation and aggression marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the acute agitation and aggression market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the acute agitation and aggression market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the acute agitation and aggression market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of acute agitation and aggression across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute agitation and aggression by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of acute agitation and aggression by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with acute agitation and aggression across the seven major markets?
• What is the size of the acute agitation and aggression patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of acute agitation and aggression?
• What will be the growth rate of patients across the seven major markets?
   

Acute Agitation and Aggression: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for acute agitation and aggression drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the acute agitation and aggression market?
• What are the key regulatory events related to the acute agitation and aggression market?
• What is the structure of clinical trial landscape by status related to the acute agitation and aggression market?
• What is the structure of clinical trial landscape by phase related to the acute agitation and aggression market?
• What is the structure of clinical trial landscape by route of administration related to the acute agitation and aggression market?